Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.

Objective: To assess whether there are evident adverse effects of 17 alpha-hydroxyprogesterone caproate after in utero exposure.

Methods: This study evaluated surviving children of mothers who participated in a multicenter placebo-controlled trial of weekly intramuscular 17 alpha-hydroxyprogesterone caproate, with a 2:1 allocation to 17 alpha-hydroxyprogesterone caproate and placebo, respectively. The guardian was interviewed about the child's general health.